| [1] |
MA Yan, TIAN Gaopeng, SHI Xingwen, SUN Ting, XIE Jingjing, ZHEN Donghu.
Correlation between 25(OH)D and metabolically related fatty liver in T2DM population
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1018-1026.
|
| [2] |
MA Xiankang, YANG Lixia, CUI Yangyang, MI Denghai.
Angelica polysaccharides improve hepatic endoplasmic reticulum stress by inhibiting the expression of GRP78, p-PERK and p-Eif2α in diabetic KK-Ay mice
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 926-936.
|
| [3] |
LI Kun, LI Lulu, LI Nannan, HU Weihong, ZHOU Jianchao.
Effects of glycaemic control and CYP3A5 polymorphisms on tacrolimus trough concentrations after adult kidney transplantation
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 767-774.
|
| [4] |
HOU Ruiying, GUO Lige, JIAO Weijie, DU Lei, WU Guiyue, ZHAO Xu.
Effects of Xiaokeshu recipe on levels of serum inflammatory factors in type2 diabetic rats and its mechanism
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 377-382.
|
| [5] |
ZHANG Xuejiao, LIU Jieting, LI Luxin, CHEN Peijian, DING Minglu, SUN Mengwei, CHU Yanhui, ZHANG Zhen .
Effects and mechanism of dapagliflozin on myocardial injury in type 1 diabetes mice
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 257-265.
|
| [6] |
ZHAO Shifeng, SONG Xiangming, YAO Jianping.
Tirzepatide: A new glucagon-like peptide-1 receptor/glucose-dependent insulinotropic peptide receptor dual agonist
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 220-227.
|
| [7] |
DU Xiaoyu, LI Yumeng, WU Huizhen, QIU Bo.
Pharmacological and clinical evaluation of Dorzagliatin in the treatment of type 2 diabetes
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1177-1183.
|
| [8] |
CAI Jing, PAN Binjing, LIU Jingfang.
Research progress on the relationship between hypoglycemic drugs and sarcopenia
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 101-108.
|
| [9] |
ZHAI Weiwei, YU Qiaoling, LIU Ping, QIU Bo, WU Huizhen.
Research progress of finerenone in the treatment of type 2 diabetes mellitus complicated with chronic kidney disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1067-1074.
|
| [10] |
LU Senlin, LIU Xinyuan, WANG Jili, HUANG Xiaofei.
Research progress of virus-mediated gene therapy in type 2 diabetes mellitu
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 800-807.
|
| [11] |
ZENG Xiaofan, XU Yiqi, LIU Shu, WU Qian, LI Zibao, HE Junjun, JIN Yuelong, ZHAO Yongli, HE Chunling, GAO Jialin.
Retrospectively analysis of the effect of low-dose aspirin on primary prevention of non-fatal myocardial infarction and cerebral infarction in patients with type 2 diabetes mellitus
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 665-671.
|
| [12] |
LI Hao, LI Ling, XIA Zhiping, YE Qifa, PENG Guizhu.
FXR agonist GW4064 ameliorates tacrolimus-induced abnormalities in glucose metabolism
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 466-472.
|
| [13] |
SHAO Xi, YU Yanan, HUANG Yuhan, WANG Xiaotong, LING Hongwei, LV Dongmei, WANG Tao.
Predictive factors associated with weight response to exenatide in patients with type 2 diabetes mellitus
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 287-294.
|
| [14] |
LV Xiaohan, LIN Rong.
Association of Lin28 with tumor, cardiovascular disease and diabetes
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 205-211.
|
| [15] |
DAI Hongyu, YANG Kun, HU Ruchun, ZHOU Hongmei, MA Peimin, HAO Qian.
Duration time and effectiveness of 0.25%ropivacaine for sciatic nerve block in patients with diabetes
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1278-1284.
|
